Axsome Therapeutics
AXSM
244 hedge funds and large institutions have $3.08B invested in Axsome Therapeutics in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 70 increasing their positions, 87 reducing their positions, and 24 closing their positions.
83% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 24
78% more call options, than puts
Call options by funds: $79.2M | Put options by funds: $44.4M
30% more funds holding in top 10
Funds holding in top 10: 10 → 13 (+3)
16% more capital invested
Capital invested by funds: $2.65B → $3.08B (+$428M)
8% more funds holding
Funds holding: 226 → 244 (+18)
1.39% more ownership
Funds ownership: 80.28% → 81.66% (+1.4%)
20% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 87
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$37.2M |
| 2 |
Millennium Management
New York
|
+$27.2M |
| 3 |
Morgan Stanley
New York
|
+$21.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.4M |
| 5 |
BlackRock
New York
|
+$20.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$65.3M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$20.9M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$16.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$13.8M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$10M |
AXSM Hedge Fund Activity: Q4 2023 in Review
244 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2023, worth a combined $3.08B — up 16% from $2.65B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new AXSM positions and 24 closed out — a net gain of 20 holders — while 70 added to existing stakes and 87 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $37.2M. The largest seller was Fidelity Investments, cutting an estimated $65.3M.
- 244 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2023, up from 226 in Q3 2023.
- Funds reported $3.08B of Axsome Therapeutics stock for Q4 2023, up 16% quarter-over-quarter.
- 44 funds opened new Axsome Therapeutics positions in Q4 2023 and 24 closed out, a net change of +20 holders.
- The largest Axsome Therapeutics buyer in Q4 2023 was Perceptive Advisors, an estimated $37.2M added.
- The largest Axsome Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $65.3M sold.
Based on aggregated 13F filings for Q4 2023.